U.S. Markets for Interventional Cardiology Products, April 2016
U.S. Markets for Interventional Cardiology Products, April 2016
$4,750.00
In the United States (U.S.), approximately 85.6 million adults have at least one type of cardiovascular disease (CVD), a broad group of disorders that affect the heart and circulatory system. Cardiovascular disease in all its forms accounts for more deaths than any other major cause in the U.S.
Publisher: Medtech Insight
- Description
- Contents
- Samples
In the United States (U.S.), approximately 85.6 million adults have at least one type of cardiovascular disease (CVD), a broad group of disorders that affect the heart and circulatory system. Cardiovascular disease in all its forms accounts for more deaths than any other major cause in the U.S., including cancer, with one of every three deaths in the country due to CVD and over 2,200 people dying from the disease each day (or an average of one death from CVD every 40 seconds). Diseases/disorders of the heart are managed using a variety of methods including noninvasive imaging, open surgery, and catheter-based modalities. Interventional cardiology is a continually evolving area of medicine that involves the use of catheter-based, or transcatheter, tools and techniques to diagnose and treat coronary vascular and structural disorders. Today, interventional techniques are a mainstay for the diagnosis and treatment of patients with CHD and certain other types of CVD, as the transcatheter procedures typically are more cost-effective and less traumatic to patients than open surgical methods. The overall market for interventional cardiology products used in the treatment of coronary artery disease was valued at $3,345.1 million in 2015. Over the forecast period covered by this report, total sales are expected to increase at a compound annual growth rate of 1.2%, reaching an estimated $3,558.7 million by the year 2020.
This report will cover:
• interventional diagnostic and therapeutic products for the treatment of CVD;
• procedure and market forecasts for the years 2015 to 2020;
• key market drivers and limiters;
• estimated revenues and market shares for major U.S. competitors; and,
• analysis of lead products and emerging products/technologies.
EXECUTIVE SUMMARY…………………………………………………………………………. ES-1
i. Diagnostic Interventional Cardiology Products …………………………. ES-2
ii. Therapeutic Interventional Cardiology Products……………………….. ES-3
iii. Methodology……………………………………………………………………….. ES-5
Exhibit ES-1: Diagnostic Interventional Cardiology Systems Market Share, by Product Segment, 2015 and 2020………………………………………….. ES-4
Exhibit ES-2: Therapeutic Interventional Systems Market Share, by Product Segment, 2015 and 2020 ……………………………………………………… ES-6
1. HEART DISEASE OVERVIEW………………………………………………………….. 1-1
1.1 Coronary Heart Disease………………………………………………………….. 1-1
1.1.1 Atherosclerosis………………………………………………………… 1-2
1.1.2 Angina Pectoris ……………………………………………………….. 1-2
1.1.3 Myocardial Infarction ………………………………………………… 1-4
1.2 Hypertension …………………………………………………………………………. 1-8
1.3 Cardiomyopathy …………………………………………………………………… 1-11
1.4 Congenital Heart Defects ………………………………………………………. 1-11
1.5 Heart Failure………………………………………………………………………… 1-14
1.5.1 Disease Development …………………………………………….. 1-14
Exhibit 1-1: Statistics for Selected Coronary Heart Disease Risk Factors………… 1-3
Exhibit 1-2: Angina Pectoris, Selected Statistics ………………………………………….. 1-5
Exhibit 1-3: Clinical Classification of AMI …………………………………………………… 1-7
Exhibit 1-4: Myocardial Infarction, Selected Statistics …………………………………… 1-9
Exhibit 1-5: Hypertension, Selected Statistics ……………………………………………. 1-10
Exhibit 1-6: Cardiomyopathy, Selected Statistics ……………………………………….. 1-12
Exhibit 1-7: Congenital Heart Defects, Selected Statistics …………………………… 1-15
Exhibit 1-8: Summary, American College of Cardiology/American Heart Association Heart Failure Staging System……………………….. 1-17
Exhibit 1-9: Heart Failure, Selected Statistics ……………………………………………. 1-18
2. DIAGNOSTIC INTERVENTIONAL CARDIOLOGY PROCEDURES AND PRODUCTS……………………………………………………………………………………. 2-1
2.1 Coronary Angiography…………………………………………………………….. 2-2
2.1.1 Procedure Volumes………………………………………………….. 2-8
2.1.2 Products …………………………………………………………………. 2-8
Exhibit ES-1: Diagnostic Interventional Cardiology Systems Market Share, by Product Segment, 2015 and 2020
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Visudyne 
Sign up to the